Trial Profile
A Single Center, Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge) as Neoadjuvant Treatment in Men With Localized Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms NeoACT
- Sponsors Dendreon Corporation
- 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Apr 2013 Planned End Date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.